Chronic Toxoplasma infection affects gene expression of drug-metabolizing enzymes in mouse liver

References

• Aitken AE, Morgan ET. 2007. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 35(9):1687–1693. doi: 10.1124/dmd.107.015511.
   PubMed Web of Science ®Google Scholar
• Aitken AE, Richardson TA, Morgan ET. 2006. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 46:123–149. doi: 10.1146/annurev.pharmtox.46.120604.141059.
   PubMed Web of Science ®Google Scholar
• Azam YJ, Machavaram KK, Rostami-Hodjegan A. 2014. The modulating effects of endogenous substances on drug metabolising enzymes and implications for inter-individual variability and quantitative prediction. Curr Drug Metab. 15(6):599–619. doi: 10.2174/1389200215666140926151642.
   PubMed Web of Science ®Google Scholar
• Berg-Candolfi M, Candolfi E. 1996. Depression of the N-demethylation of erythromycin, azithromycin, clarithromycin and clindamycin in murine Toxoplasma infection. Int J Parasitol. 26(11):1321–1323. doi: 10.1016/s0020-7519(96)00111-7.
   PubMed Web of Science ®Google Scholar
• Berg-Candolfi M, Candolfi E, Benet LZ. 1996. Suppression of intestinal and hepatic cytochrome P4503A in murine Toxoplasma infection. Effects of N-acetylcysteine and NG-monomethyl-L-arginine on the hepatic suppression. Xenobiotica. 26(4):381–394. doi: 10.3109/00498259609046717.
   PubMed Web of Science ®Google Scholar
• Garfoot AL, Wilson GM, Coon JJ, Knoll LJ. 2019. Proteomic and transcriptomic analyses of early and late-chronic Toxoplasma gondii infection shows novel and stage specific transcripts. BMC Genomics. 20(1):859. doi: 10.1186/s12864-019-6213-0.
   PubMed Web of Science ®Google Scholar
• He JJ, Ma J, Elsheikha HM, Song HQ, Huang SY, Zhu XQ. 2016. Transcriptomic analysis of mouse liver reveals a potential hepato-enteric pathogenic mechanism in acute Toxoplasma gondii infection. Parasit Vectors. 9(1):427.
   PubMedGoogle Scholar
• He JJ, Ma J, Wang JL, Zhang FK, Li JX, Zhai BT, Wang ZX, Elsheikha HM, Zhu XQ. 2019. Global transcriptome profiling of multiple porcine organs reveals Toxoplasma gondii-induced transcriptional landscapes. Front Immunol. 10:1531. doi: 10.3389/fimmu.2019.01531.
   PubMed Web of Science ®Google Scholar
• Hrycay EG, Bandiera SM. 2009. Expression, function and regulation of mouse cytochrome P450 enzymes: comparison with human P450 enzymes. Curr Drug Metab. 10(10):1151–1183. doi: 10.2174/138920009790820138.
   PubMed Web of Science ®Google Scholar
• Hu RS, He JJ, Elsheikha HM, Zou Y, Ehsan M, Ma QN, Zhu XQ, Cong W. 2020. Transcriptomic profiling of mouse brain during acute and chronic infections by Toxoplasma gondii oocysts. Front Microbiol. 11:570903. doi: 10.3389/fmicb.2020.570903.
   PubMed Web of Science ®Google Scholar
• Kandel SE, Han LW, Mao Q, Lampe JN. 2017. Digging deeper into CYP3A testosterone metabolism: kinetic, regioselectivity, and stereoselectivity differences between CYP3A4/5 and CYP3A7. Drug Metab Dispos. 45(12):1266–1275. doi: 10.1124/dmd.117.078055.
   PubMed Web of Science ®Google Scholar
• Klaassen CD, Slitt AL. 2005. Regulation of hepatic transporters by xenobiotic receptors. Curr Drug Metab. 6(4):309–328. doi: 10.2174/1389200054633826.
   PubMed Web of Science ®Google Scholar
• Konstantinovic N, Guegan H, Stäjner T, Belaz S, Robert-Gangneux F. 2019. Treatment of toxoplasmosis: current options and future perspectives. Food Waterborne Parasitol. 15:e00036. doi: 10.1016/j.fawpar.2019.e00036.
   PubMedGoogle Scholar
• Löfgren S, Hagbjörk AL, Ekman S, Fransson-Steen R, Terelius Y. 2004. Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison. Xenobiotica. 34(9):811–834. doi: 10.1080/00498250412331285463.
   PubMed Web of Science ®Google Scholar
• Masatani T, Oyamada S, Inoue R, Tsujio M, Hatai H, Matsui T, Matsuo T. 2020. In vivo characterization of a Toxoplasma gondii strain TgCatJpTy1/k-3 isolated from a stray cat in Japan. Parasitol Int. 74:101995. doi: 10.1016/j.parint.2019.101995.
   PubMed Web of Science ®Google Scholar
• Montoya JG, Liesenfeld O. 2004. Toxoplasmosis. Lancet. 363(9425):1965–1976. doi: 10.1016/S0140-6736(04)16412-X.
   PubMed Web of Science ®Google Scholar
• Morgan ET. 2009. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 85(4):434–438. doi: 10.1038/clpt.2008.302.
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Uehara S, Kusama T, Inoue T, Shimura K, Kamiya Y, Murayama N, Shimizu M, Uno Y, Sasaki E, et al. 2018. In vivo and in vitro diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants. Biochem Pharmacol. 152(6):272–278. doi: 10.1016/j.bcp.2018.04.002.
   PubMedGoogle Scholar
• Pittman KJ, Aliota MT, Knoll LJ. 2014. Dual transcriptional profiling of mice and Toxoplasma gondii during acute and chronic infection. BMC Genomics. 15(1):806. doi: 10.1186/1471-2164-15-806.
   PubMedGoogle Scholar
• Rendic S. 2002. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 34:83–448. doi: 10.1081/dmr-120001392.
   PubMed Web of Science ®Google Scholar
• Robert-Gangneux F, Darde ML. 2012. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 25(2):264–296. doi: 10.1128/CMR.05013-11.
   PubMed Web of Science ®Google Scholar
• Shah RR, Smith RL. 2015. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos. 43(3):400–410. doi: 10.1124/dmd.114.061093.
   PubMed Web of Science ®Google Scholar
• Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R, French Society of P, Therapeutics. 2020. Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharmacol Ther. 215:107627. doi: 10.1016/j.pharmthera.2020.107627.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Nishimura M, Ihara F, Yamagishi J, Suzuki Y, Nishikawa Y. 2013. Transcriptome analysis of mouse brain infected with Toxoplasma gondii. Infect Immun. 81(10):3609–3619. doi: 10.1128/IAI.00439-13.
   PubMed Web of Science ®Google Scholar
• Tenter AM, Heckeroth AR, Weiss LM. 2000. Toxoplasma gondii: from animals to humans. Int J Parasitol. 30(12–13):1217–1258. doi: 10.1016/s0020-7519(00)00124-7.
   PubMed Web of Science ®Google Scholar
• Uehara S, Higuchi Y, Yoneda N, Yamazaki H, Suemizu H. 2021. UDP-glucuronosyltransferase 1A4-mediated N2-glucuronidation is the major metabolic pathway of lamotrigine in chimeric NOG-TKm30 mice with humanised-livers. Xenobiotica. 51(10):1146–1154. doi: 10.1080/00498254.2021.1972492.
   PubMed Web of Science ®Google Scholar
• Uehara S, Uno Y, Inoue T, Kawano M, Shimizu M, Toda A, Utoh M, Sasaki E, Yamazaki H. 2015. Novel marmoset cytochrome P450 2C19 in livers efficiently metabolizes human P450 2C9 and 2C19 substrates, S-warfarin, tolbutamide, flurbiprofen, and omeprazole. Drug Metab Dispos. 43(10):1408–1416. doi: 10.1124/dmd.115.066100.
   PubMed Web of Science ®Google Scholar
• Uehara S, Uno Y, Inoue T, Kawano M, Shimizu M, Toda A, Utoh M, Sasaki E, Yamazaki H. 2016. Individual differences in metabolic clearance of S-warfarin efficiently mediated by polymorphic marmoset cytochrome P450 2C19 in livers. Drug Metab Dispos. 44(7):911–915. doi: 10.1124/dmd.116.070383.
   PubMed Web of Science ®Google Scholar
• Uehara S, Yoneda N, Higuchi Y, Yamazaki H, Suemizu H. 2021. Methyl-hydroxylation and subsequent oxidation to produce carboxylic acid is the major metabolic pathway of tolbutamide in chimeric TK-NOG mice transplanted with human hepatocytes. Xenobiotica. 51(5):582–589. doi: 10.1080/00498254.2021.1875515.
   PubMed Web of Science ®Google Scholar
• Uehara S, Murayama N, Higuchi Y, Yoneda N, Yamazaki H, Suemizu H. 2022. Comparison of mouse and human cytochrome P450 mediated-drug metabolising activities in hepatic and extrahepatic microsomes. Xenobiotica 52(3):229–239. doi:10.1080/00498254.2022.2066581.
   PubMed Web of Science ®Google Scholar
• Uno Y, Uehara S, Yamazaki H. 2016. Utility of non-human primates in drug development: comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes. Biochem Pharmacol. 121:1–7. doi: 10.1016/j.bcp.2016.06.008.
   PubMed Web of Science ®Google Scholar
• Uno Y, Uehara S, Yamazaki H. 2022. Drug-oxidizing and conjugating non-cytochrome P450 (non-P450) enzymes in cynomolgus monkeys and common marmosets as preclinical models for humans. Biochem Pharmacol. 197:114887. doi: 10.1016/j.bcp.2021.114887.
   PubMed Web of Science ®Google Scholar
• Winter HR, Unadkat JD. 2005. Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 33(7):969–976. doi: 10.1124/dmd.104.002998.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shimada T. 1997. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 346(1):161–169. doi: 10.1006/abbi.1997.0302.
   PubMed Web of Science ®Google Scholar